Pharmaceuticals
RoboPharma Acquired by Capsa Healthcare to Broaden Reach Into New Pharmacy Automation Markets
WAALWIJK, Netherlands, Aug. 26, 2020 /PRNewswire/ -- RoboPharma announced today the company has been acquired by Capsa Healthcare, a worldwide innovator in healthcare delivery solutions for hospitals, senior care settings, and retail pharmacy providers. Becoming an integral segment within Capsa H...
2020-08-26 08:12
2512
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors
NORTH BRUNSWICK, N.J., Aug. 24, 2020 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that the first patient has been dosed in a phase1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in c...
2020-08-24 13:13
1541
111, Inc. Announces Second Quarter 2020 Unaudited Financial Results
SHANGHAI, Aug. 20, 2020 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a company dedicated to digitally connecting patients with drugs and healthcare services inChina, today announced its unaudited financial results for the second quarter endedJune 30, 2020. Second Quarter 2020...
2020-08-20 16:35
11605
China Biologic Reports Financial Results for the Second Quarter of 2020
BEIJING, Aug. 17, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the second quarter of 2020. Second Quart...
2020-08-18 04:30
10003
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed with plonmarlimab ...
2020-08-17 20:00
3611
CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion
SHANGHAI, Aug. 17, 2020 /PRNewswire/ -- CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, today announced its publication of the 7×21 CAR-T technology in CLINICAL CANCER RESEARCH. The article is titled "Coexpression of IL-7 and CCL21 increases efficacy ...
2020-08-17 18:00
4167
Bushu Pharmaceuticals Announces Major Expansion Program
KAWAGOE, Japan, Aug. 14, 2020 /PRNewswire/ -- - Japan's Premier CDMO Will Invest $100m to Expand Capacity and Portfolio - Bushu Pharmaceuticals Ltd., one of Japan's largest contract manufacturers of pharmaceutical products, announced onAugust 14 a major capital program costing $100 million to ex...
2020-08-14 14:00
2635
China Biologic Products to Report Second Quarter 2020 Financial Results
BEIJING, Aug. 10, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its second quarter 2020 financial results ...
2020-08-10 20:00
8925
CMAB Appoints Ms. Maggie Chen as Chief Financial Officer
SUZHOU, China, Aug. 6, 2020 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc. ("CMAB"), a dedicated biologics contract manufacturing and development organization (CDMO), today announced the appointment of Ms.Maggie Chen as the chief financial officer. Ms. Chen will lay a solid foundation for the long-...
2020-08-07 08:00
4654
ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies
SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immun...
2020-08-06 23:49
9601
I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020
SHANGHAI and GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the six months ...
2020-08-06 20:30
14873
Samsung Biologics launches S-CHOice cell line expression technology
INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX:
207940.KS) today held an online ceremony to announce the launch of its
proprietary cell line technology, S-CHOice.
2020-08-05 09:09
2979
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration (...
2020-08-04 20:17
15905
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for present...
2020-08-04 09:33
7740
111 to Announce Second Quarter 2020 Unaudited Financial Results on August 20, 2020
SHANGHAI, July 31, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a Company dedicated to digitally connecting patients with drugs and healthcare services inChina, today announced that it will report its unaudited financial results for the second quarter endedJune 30, 2020, ...
2020-07-31 18:00
9958
Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report
Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with minimum NASDAQ price * End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity Therap...
2020-07-31 06:49
17043
New Findings from AAIC Indicated Brain-Gut Axis to be the New Breakthrough in the Research Field of Alzheimer's Disease
SHANGHAI, July 29, 2020 /PRNewswire/ -- Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but f...
2020-07-29 15:28
1722
Viva Biotech and Schrödinger Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based drug discovery by generatingde novo crystal structures of high-value targets. Under the terms ...
2020-07-29 07:00
11203
I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer
SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment of Mr.Ivan Yifei Zhu as its Chief Commer...
2020-07-28 20:22
10248
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg
TAIPEI, Taiwan, July 27, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for Camcevi™ 42mg (FP-001 LMIS 50mg), a ready-to-use 6-month depot formulation of...
2020-07-28 12:34
2016
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 287 media titles]
2025-01-14 21:00
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20322
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6480
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5610
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4945
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4926
